DK1888614T3 - Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre - Google Patents

Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre

Info

Publication number
DK1888614T3
DK1888614T3 DK06763188.7T DK06763188T DK1888614T3 DK 1888614 T3 DK1888614 T3 DK 1888614T3 DK 06763188 T DK06763188 T DK 06763188T DK 1888614 T3 DK1888614 T3 DK 1888614T3
Authority
DK
Denmark
Prior art keywords
beta
alkyl
dihydroxy
5beta
6alpha
Prior art date
Application number
DK06763188.7T
Other languages
English (en)
Inventor
Massimo Ferrari
Roberto Pellicciari
Original Assignee
Erregierre Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erregierre Spa filed Critical Erregierre Spa
Application granted granted Critical
Publication of DK1888614T3 publication Critical patent/DK1888614T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Seasonings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06763188.7T 2005-05-19 2006-05-19 Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre DK1888614T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000912A ITMI20050912A1 (it) 2005-05-19 2005-05-19 Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
PCT/EP2006/062446 WO2006122977A2 (en) 2005-05-19 2006-05-19 PROCESS FOR PREPARING 3α(β)-7α(β)-DIHYDROXY-6α(β)-ALKYL-5β-CHOLANIC ACID

Publications (1)

Publication Number Publication Date
DK1888614T3 true DK1888614T3 (da) 2010-05-10

Family

ID=35841713

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06763188.7T DK1888614T3 (da) 2005-05-19 2006-05-19 Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre

Country Status (12)

Country Link
US (1) US7994352B2 (da)
EP (1) EP1888614B1 (da)
JP (1) JP5127700B2 (da)
CN (1) CN101203526B (da)
AT (1) ATE453657T1 (da)
AU (1) AU2006248906B2 (da)
CA (1) CA2608539C (da)
DE (1) DE602006011457D1 (da)
DK (1) DK1888614T3 (da)
ES (1) ES2338698T3 (da)
IT (1) ITMI20050912A1 (da)
WO (1) WO2006122977A2 (da)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48286E1 (en) 2001-03-12 2020-10-27 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
EP1734970B1 (en) 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
CN101679476B (zh) 2007-01-19 2014-05-07 英特塞普特医药品公司 23取代的胆汁酸作为tgr5调节剂及其使用方法
WO2010014836A2 (en) 2008-07-30 2010-02-04 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
PL2698375T3 (pl) 2008-11-19 2018-08-31 Intercept Pharmaceuticals, Inc. Modulatory TGR5 i sposób ich zastosowania
JP5810413B2 (ja) 2008-12-19 2015-11-11 バイオジェン インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗アルファシヌクレイン自己抗体
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
KR102106186B1 (ko) * 2012-11-28 2020-05-04 인터셉트 파마슈티컬즈, 인크. 폐 질환의 치료
JP6621409B2 (ja) 2013-11-22 2019-12-18 ミナ セラピューティクス リミテッド Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
EP3149019B1 (en) * 2014-05-29 2019-12-04 Bar Pharmaceuticals S.r.l. Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases
WO2016045480A1 (zh) * 2014-09-28 2016-03-31 上海源力生物技术有限公司 一种奥贝胆酸的制备方法
CN105585603B (zh) * 2014-10-21 2019-05-24 重庆医药工业研究院有限责任公司 一种制备奥贝胆酸中间体的方法
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
CN111944006B (zh) * 2014-11-17 2021-12-17 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
EP3221334B1 (en) * 2014-11-19 2020-02-19 Nzp Uk Limited 6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
TWI686401B (zh) * 2014-11-19 2020-03-01 英商Ｎｚｐ英國有限公司 化合物（三）
KR102526632B1 (ko) * 2014-11-19 2023-04-27 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드
CN107207559B (zh) * 2014-11-19 2019-10-25 Nzp英国有限公司 作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
KR20170099909A (ko) 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN104558086B (zh) * 2014-12-25 2016-10-05 康美（北京）药物研究院有限公司 一种5β-3α,7α-二羟基-6α-乙基-胆烷酸的制备方法
CN105777835B (zh) * 2014-12-25 2020-02-14 重庆药友制药有限责任公司 一种制备鹅去氧胆酸类似物的方法
CN105859814A (zh) * 2015-01-23 2016-08-17 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及其药物组合物
CA2976056C (en) 2015-02-06 2024-02-06 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
BR112017017238A2 (pt) 2015-02-11 2018-04-10 Enanta Pharm Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
CN105985395A (zh) * 2015-02-13 2016-10-05 江苏奥赛康药业股份有限公司 一种奥贝胆酸化合物及含有该化合物的药物组合物
EP3277286B1 (en) 2015-03-31 2021-04-21 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PE20180034A1 (es) 2015-04-07 2018-01-09 Intercept Pharmaceuticals Inc Composiciones farmaceuticas para terapias combinadas
CN105777836A (zh) * 2015-04-09 2016-07-20 厦门蔚扬药业有限公司 奥贝胆酸的多晶型物及其制备方法
CN106256833B (zh) * 2015-06-19 2019-01-11 中国人民解放军军事医学科学院毒物药物研究所 制备3,7-二(三甲基硅基氧基)-6-烯-5β-胆烷-24-酸甲酯的方法
CN105294801A (zh) * 2015-07-02 2016-02-03 扬子江药业集团南京海陵药业有限公司 6-乙基鹅去氧胆酸异构体的合成及其分离测定方法
CZ2015504A3 (cs) 2015-07-16 2017-01-25 Zentiva, K.S. Krystalické formy obeticholové kyseliny
CN106397522A (zh) * 2015-07-31 2017-02-15 中国人民解放军军事医学科学院毒物药物研究所 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途
CN105085597B (zh) * 2015-08-28 2017-03-29 成都百裕制药股份有限公司 一种无定型奥贝胆酸的制备方法
CN106478756A (zh) * 2015-09-02 2017-03-08 中美华世通生物医药科技（武汉）有限公司 Oca-e单晶及其制备方法和用途
JP6824966B2 (ja) 2015-09-21 2021-02-03 インターセプト ファーマシューティカルズ， インコーポレイテッド 肝臓の再生を促進する方法
AU2016325619A1 (en) 2015-09-24 2018-04-12 Intercept Pharmaceuticals, Inc. Methods and intermediates for the preparation bile acid derivatives
CN106589038A (zh) * 2015-10-15 2017-04-26 重庆医药工业研究院有限责任公司 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法
CN106632564B (zh) * 2015-10-30 2021-04-13 苏州泽璟生物制药股份有限公司 奥贝胆酸盐及其无定形物和药物组合物
AU2016350690C1 (en) 2015-11-06 2020-04-23 Intercept Pharmaceuticals, Inc. Methods for the preparation of obeticholic acid and derivatives thereof
CN106749466B (zh) * 2015-11-23 2019-05-21 南京济群医药科技股份有限公司 一种高纯度奥贝胆酸的制备方法
CN105315320B (zh) * 2015-11-30 2017-03-08 山东省药学科学院 一种制备奥贝胆酸的方法
CN106810586A (zh) * 2015-12-01 2017-06-09 中美华世通生物医药科技（武汉）有限公司 奥贝胆酸晶型ⅱ及其制备方法和用途
CN105481925B (zh) * 2015-12-17 2018-06-22 南京济群医药科技股份有限公司 一种奥贝胆酸及其中间体的制备方法
MX2018007776A (es) * 2015-12-22 2018-08-09 Intercept Pharmaceuticals Inc Formas polimorficas cristalinas del acido obeticolico.
CN105646633B (zh) * 2016-01-22 2020-05-26 南京长澳医药科技有限公司 一种制备奥贝胆酸1型的方法
US11168107B2 (en) 2016-02-10 2021-11-09 Dr. Reddy's Laboratories Limited Amine salt of obeticholic acid
WO2017147159A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
CN105585605A (zh) * 2016-03-15 2016-05-18 成都市新功生物科技有限公司 一种奥贝胆酸中间体的合成方法
CN105541953B (zh) * 2016-03-15 2017-11-21 成都市新功生物科技有限公司 一种高纯度奥贝胆酸的重结晶纯化方法
EP3440092A1 (en) 2016-04-04 2019-02-13 Dipharma Francis S.r.l. Method for preparing a farnesoid x receptor agonist
JP6968821B2 (ja) 2016-04-13 2021-11-17 インターセプト ファーマシューティカルズ， インコーポレイテッド 癌を治療する方法
TW201738254A (zh) 2016-04-19 2017-11-01 英特賽普醫藥品公司 奧貝膽酸及其衍生物之製備方法
GB201608779D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
GB201608776D0 (en) * 2016-05-18 2016-06-29 Dextra Lab Ltd Methods and compounds
CN107400154A (zh) * 2016-05-18 2017-11-28 北京凯因科技股份有限公司 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
CN106046094A (zh) * 2016-05-30 2016-10-26 福建广生堂药业股份有限公司 一种奥贝胆酸二聚体杂质及其制备方法
WO2017207648A1 (en) 2016-05-31 2017-12-07 Bionice, S.L.U Process and intermediates for the preparation of obeticholic acid and derivatives thereof
WO2017208165A1 (en) 2016-06-01 2017-12-07 Dr. Reddy’S Laboratories Limited Process for preparation of obeticholic acid
CN106083971B (zh) * 2016-06-17 2017-11-14 苏州敬业医药化工有限公司 一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法
CZ2016385A3 (cs) 2016-06-28 2018-01-10 Zentiva, K.S. Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny
WO2018010651A1 (zh) * 2016-07-13 2018-01-18 江苏恒瑞医药股份有限公司 一种奥贝胆酸及其中间体的制备方法
CN107663221A (zh) * 2016-07-27 2018-02-06 南京长澳医药科技有限公司 一种奥贝胆酸的制备方法
CN106279335A (zh) * 2016-08-12 2017-01-04 齐鲁制药有限公司 一种制备奥贝胆酸及其中间体的方法
EP3287467A1 (en) 2016-08-22 2018-02-28 ratiopharm GmbH Preparation of obeticholic acid comprising continuous flow process steps
CN109641934B (zh) * 2016-09-20 2021-07-02 江苏豪森药业集团有限公司 胆酸衍生物游离碱，晶型及其制备方法和应用
CN106478757B (zh) * 2016-09-27 2019-01-18 华南理工大学 一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法
CN107936078A (zh) * 2016-10-13 2018-04-20 上海科胜药物研发有限公司 一种制备奥贝胆酸的新方法
CN108070014A (zh) * 2016-11-08 2018-05-25 北京藏卫信康医药研发有限公司 一种化合物的制备方法及其在制备奥贝胆酸中的应用
WO2018102418A1 (en) * 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
CN108117579A (zh) * 2016-11-29 2018-06-05 昆明积大制药股份有限公司 奥贝胆酸及其中间体的制备方法
WO2018152171A1 (en) 2017-02-14 2018-08-23 Enanta Pharmaceuticals, Inc. Bile acid derivatives as fxr agonists and methods of use thereof
CN108456238A (zh) * 2017-02-20 2018-08-28 浙江京新药业股份有限公司 奥贝胆酸衍生物及奥贝胆酸的制备方法
SG11201906987RA (en) 2017-02-21 2019-09-27 Genfit Combination of a ppar agonist with a fxr agonist
EP3606533B1 (en) 2017-04-07 2023-11-15 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
JP6987967B2 (ja) * 2017-04-20 2022-01-05 デーウン・バイオ・インコーポレイテッド 連続フロー反応を利用した胆汁酸誘導体の製造方法
CN107298694A (zh) * 2017-04-21 2017-10-27 华东师范大学 奥贝胆酸的合成方法及其中间体
CZ2017298A3 (cs) 2017-05-26 2018-12-05 Zentiva, K.S. Amorfní formy obeticholové kyseliny
EP3431486A1 (en) 2017-07-18 2019-01-23 Bionice, S.L.U. Process and intermediates for the synthesis of obeticholic acid and derivatives thereof
CA3070853C (en) 2017-08-03 2023-01-03 Medytox Inc. Methods for preparing bile acids
EP3679139B1 (en) 2017-09-08 2022-11-02 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
CN108299539B (zh) * 2018-03-09 2021-07-06 中山百灵生物技术股份有限公司 利用连续流微反应器生产6-亚乙基鹅去氧胆酸的方法
CN110655550A (zh) * 2018-06-29 2020-01-07 江苏海悦康医药科技有限公司 (E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法
GB201812382D0 (en) 2018-07-30 2018-09-12 Nzp Uk Ltd Compounds
US20210261599A1 (en) 2018-08-24 2021-08-26 Solara Active Pharma Sciences Limited Process for the Preparation of Obeticholic Acid and Intermediates Used In the Process Thereof
CN109485686B (zh) * 2018-12-27 2021-08-27 重庆华邦胜凯制药有限公司 一种提高琥珀酸甲泼尼龙杂质合成中关键中间体6β含量的方法
CN111718388A (zh) 2019-03-19 2020-09-29 苏州泽璟生物制药股份有限公司 鹅去氧胆酸衍生物的制备方法
KR20220016146A (ko) 2019-05-30 2022-02-08 인터셉트 파마슈티컬즈, 인크. 담즙정체성 간 질환의 치료에서 사용하기 위한 fxr 효능제 및 피브레이트를 포함하는 제약 조성물
CN112898369A (zh) * 2019-12-04 2021-06-04 博瑞生物医药（苏州）股份有限公司 用于制备奥贝胆酸的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3366932D1 (en) 1982-07-29 1986-11-20 Lehner Ag New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same
IT1206112B (it) 1983-04-29 1989-04-14 Lehner Ag Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT1212835B (it) 1983-08-18 1989-11-30 Lehner Ag Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche.
US4892868A (en) * 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1196377B (it) 1984-12-21 1988-11-16 Lehner Ag Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT1223313B (it) * 1987-10-20 1990-09-19 Gipharmex Spa Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono
IT1229570B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
US5175320A (en) * 1989-04-17 1992-12-29 Giuliani S.P.A. Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5055477A (en) * 1989-12-13 1991-10-08 Mitsubishi Kasei Corporation Pyrazolyl acrylic acid derivatives, useful as systemic fungicides for plant and material protection
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
AU3552697A (en) 1996-07-12 1998-02-09 Smithkline Beecham Plc Novel treatment of leptine resistance
US6008237A (en) * 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
EP1053227B1 (en) 1998-01-29 2008-11-05 Amgen Inc. Ppar-gamma modulators
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
CA2356887A1 (en) * 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
US6465258B1 (en) 1999-01-07 2002-10-15 Tularik, Inc. FXR receptor-mediated modulation cholesterol metabolism
US20020132223A1 (en) * 1999-03-26 2002-09-19 City Of Hope Methods for modulating activity of the FXR nuclear receptor
EP1473042B1 (en) 1999-03-26 2006-06-21 City of Hope Screening for FXR receptor modulators
JP2004510682A (ja) 1999-03-26 2004-04-08 シティ・オブ・ホープ 核胆汁酸受容体を用いコレステロール異化作用に影響を与える方法
CA2377320A1 (en) 1999-06-11 2000-12-21 Allergan Sales, Inc. Methods for modulating fxr receptor activity
US6906057B1 (en) * 1999-06-11 2005-06-14 Allergan, Inc. Methods for modulating FXR receptor activity
US6559188B1 (en) * 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
JP2003525217A (ja) 1999-10-22 2003-08-26 メルク エンド カムパニー インコーポレーテッド 肥満治療用薬剤
US6627636B2 (en) * 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2002020463A2 (en) 2000-09-05 2002-03-14 Tularik Inc. Fxr modulators
US20020119958A1 (en) 2001-02-13 2002-08-29 Shinichiro Tojo Therapeutic agent for hyperlipidemia
USRE48286E1 (en) * 2001-03-12 2020-10-27 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
US7354726B2 (en) 2001-04-12 2008-04-08 Takeda Pharmaceutical Company Limited Screening method
EP1423113A4 (en) 2001-08-13 2007-04-18 Phenex Pharmaceuticals Ag NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003016280A1 (en) 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
US20030144360A1 (en) 2001-11-19 2003-07-31 Allergan Sales, Inc. Composition and method for modulating BAR/FXR receptor activity
US20050107475A1 (en) * 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
US7368152B2 (en) 2002-06-19 2008-05-06 Availvs Corporation Artificial stone wall material
AU2003290700A1 (en) 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
US20070015796A1 (en) 2003-09-26 2007-01-18 Smithkline Beecham Corporation Compositions and methods for treatment of fibrosis
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
EP1734970B1 (en) 2004-03-12 2014-12-31 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
WO2008002573A2 (en) 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
CN101679476B (zh) 2007-01-19 2014-05-07 英特塞普特医药品公司 23取代的胆汁酸作为tgr5调节剂及其使用方法
EP1947108A1 (en) 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
PL2698375T3 (pl) 2008-11-19 2018-08-31 Intercept Pharmaceuticals, Inc. Modulatory TGR5 i sposób ich zastosowania

Also Published As

Publication number Publication date
WO2006122977A2 (en) 2006-11-23
CN101203526A (zh) 2008-06-18
DE602006011457D1 (de) 2010-02-11
CA2608539A1 (en) 2006-11-23
CA2608539C (en) 2013-02-26
US20080214515A1 (en) 2008-09-04
EP1888614A2 (en) 2008-02-20
US7994352B2 (en) 2011-08-09
WO2006122977A3 (en) 2007-01-18
ITMI20050912A1 (it) 2006-11-20
JP5127700B2 (ja) 2013-01-23
ATE453657T1 (de) 2010-01-15
EP1888614B1 (en) 2009-12-30
AU2006248906A1 (en) 2006-11-23
JP2008540612A (ja) 2008-11-20
ES2338698T3 (es) 2010-05-11
CN101203526B (zh) 2012-09-05
AU2006248906B2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
DK1888614T3 (da) Fremgangsmåde til fremstilling af 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansyre
ES2338590T3 (es) Procedimiento regioselectivo de preparacion de benzoimidazoltiofenos.
DOP2010000396A (es) Derivado de uracilo o timina para el tratamiento de hepatitis c
DK1637610T3 (da) Fremgangsmåde til fremstilling af alkylestere
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2076594T3 (da) Fremgangsmåde til enzymatisk hydrolyse af forbehandlede lignocellulose-udgangsmaterialer
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
DK1893587T3 (da) Fremgangsmåde til fremstilling af dihydroquinazoliner
DK1888294T3 (da) Fremgangsmåde til hårdlodning af artikler af rustfrit stål
DOP2011000301A (es) Derivados de azaadamantano y metodos de uso de los mismos
BRPI0918648A2 (pt) anticorpos multiespecíficos
EA200702464A1 (ru) Способы получения фенольных 4-бифенилилазетидин-2-онов
DK2489662T3 (da) Mellemprodukter af en ny fremgangsmåde til fremstillingen af 5-benzyliden-2-alkylimino-3-phenylthiazolidin-4-on derivater
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
DE602006017918D1 (de) Verfahren zur Herstellung von Telmisartan
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
DK2080808T3 (da) Fremgangsmåde til fremstilling af l-aminosyre
CO6270227A2 (es) Derivados de quinazolinadiona su preparacion y sus aplicaciones terapeuticas
DK1899454T3 (da) Serumfrit kulturmedium til fremstilling af rekombinante gonadotropiner
DE602006018699D1 (de) Verfahren zur Herstellung von Fluorhalogenethern
DK1831239T3 (da) Fremgangsmåde til fremstilling af 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-carboxylsyre-lambda-lacton og nøgle-mellemprodukter til denne fremgangsmåde
DK2300606T3 (da) Fremgangsmåde til fremstilling af et kaseinhydrolysat
BRPI0514053A (pt) método para aumentar a tolerabilidade das plantas frente ao glifosato
HN2010001233A (es) Uso derivados de acido tetramico para controlar nematodos
DK2245001T3 (da) Fremgangsmåde til fremstilling af 2-fluoracyl-3-amino-acrylsyrederivater